Menu
  • Join
  • Login
  • Contact
 

Search abstracts


PHARMACOGENETIC TESTING TO IDENTIFY PRESENCE OF THE HLA-B*57:01 BIOMARKER FOR ABACAVIR TREATMENT

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: WIRTH, Francesca (UNIVERSITY OF MALTA, Pharmacy, Malta)
  • Co-author(s): Leanne Camilleri: Department of Pharmacy, University of Malta, Msida, Malta
    Francesca Wirth: Department of Pharmacy, University of Malta, Msida, Malta
    Lilian M Azzopardi: Department of Pharmacy, University of Malta, Msida, Malta
  • Abstract:

    Background

    Testing for the HLA-B*57:01 pharmacogenetic (PGx) biomarker is clinically significant to predict risk of hypersensitivity reactions in patients to be treated with abacavir.

    Methods

    A literature search was performed to identify studies describing testing for HLA-B*57:01 with respect to therapy with abacavir. The studies were reviewed and

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses